Table 3. Response and Remission Ratesa for Patients with Major Depressive Disorder Receiving an Antidepressant Plus Adjunctive Placebo or Riluzole.
|
Placebo/Placebo (N=40) |
Placebo/Riluzole (N=39) |
Riluzole/Riluzole (N=25) |
||||
|---|---|---|---|---|---|---|
| N (% Response) | N (% Remission) | N (% Response) | N (% Remission) | N (% Response) | N (% Remission) | |
| Block 1b | 6 (15.0%) | 2 (5.0%) | 5 (12.8%) | 3 (7.7%) | 2 (8.0%) | 1 (4.0%) |
| Block 2c | 4 (12.9%) | 1 (2.9%) | 3 (9.7%) | 2 (6.3%) | 4 (18.2%) | 2 (9.1%) |
| Overall | 10 (25.0% | 3 (7.5%) | 8 (20.5%) | 5 (12.8%) | 6 (24.0%) | 3 (12.0%) |
a
Response is ⩾50% improvement in MADRS score from baseline; remission is MADRS score ⩽9; last observation carried forward used within each block of 4 weeks.
b
Baseline to week 4.
c
Week 4 to week 8, among non-responders to placebo in Block 1.